Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HBV Viral Suppression by Entecavir in Adefovir Partial Responders.

Trial Profile

HBV Viral Suppression by Entecavir in Adefovir Partial Responders.

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms ADVPR
  • Most Recent Events

    • 08 May 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Planned number of patients changed from 80 to 120 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top